BioWorld

March 8, 2004

SuperGen Brings In $34M Via Private Sale Of Stock, Warrants

It seems SuperGen Inc. decided to change its course. Just weeks after disclosing plans to withdraw a proposed stock offering, the cancer drug development company raised $34 million through a stock-and-warrant sale. (BioWorld Today) Read More

FDA Requesting Feedback On Impact Of Medicare Changes

Shamrock Structures Offering 3-D Protein Structure Services

Angiotech's Technology Approved In Boston Scientific's Coated Stent

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...